As of now, Pfizer is probably one of the pharmaceutical companies that has benefited the most from the COVID-19 pandemic. The company not only took the lead in the COVID-19 vaccine research and development war, but also won a landmark victory in the development of COVID-19 therapeutics.
On November 5, 2021, Pfizer announced the results of a phase II/III mid-clinical trial of Paxlovid, an anti-COVID-19 combination therapy under development: when used in the early stages of infection, hospitalization and death rates in high-risk adult patients can be reduced by 89%.
However, as soon as the results came out, the market was shocked. While Pfizer's stock price surged 10%, it also put more pressure on other similar competitor R&D companies such as Moderna and MSD.
With the opening of the market this Monday, A-share and Hong Kong-share CDMO companies may also be dragged down by this incident, especially Pharmaceutical Biotech.
Why did Pfizer's oral COVID-19 drug cause a sharp decline in many segments, which companies may have been mistaken in the market, and which companies are likely to continue to decline?
It is also an oral COVID-19 small molecule drug. How is Pfizer different from MSD's monupivir?
The Paxlovid treatment announced by Pfizer this time includes two drugs: ritonavir, the PF-07321332+ anti-HIV drug developed by the company. In fact, PF-07321332 is a drug developed by the team against the SARS virus in 2003, which was later shelved due to the disappearance of the SARS virus.
Similarities: Pfizer therapy and MSD's monupivir are both small-molecule oral medications. They are easy to use and relatively expensive...